These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 21135860

  • 1. Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning.
    Lange T, Hubmann M, Burkhardt R, Franke GN, Cross M, Scholz M, Leiblein S, Al-Ali HK, Edelmann J, Thiery J, Niederwieser D.
    Leukemia; 2011 Mar; 25(3):498-505. PubMed ID: 21135860
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism.
    Kwon M, Martínez-Laperche C, Infante M, Carretero F, Balsalobre P, Serrano D, Gayoso J, Pérez-Corral A, Anguita J, Díez-Martín JL, Buño I.
    Biol Blood Marrow Transplant; 2012 Aug; 18(8):1235-42. PubMed ID: 22281301
    [Abstract] [Full Text] [Related]

  • 6. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
    Pérez-Simón JA, Caballero D, Diez-Campelo M, Lopez-Pérez R, Mateos G, Cañizo C, Vazquez L, Vidriales B, Mateos MV, Gonzalez M, San Miguel JF.
    Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
    [Abstract] [Full Text] [Related]

  • 7. Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis.
    Hoffmann JC, Stabla K, Burchert A, Volkmann T, Bornhäuser M, Thiede C, Neubauer A, Brendel C.
    Ann Hematol; 2014 Feb; 93(2):279-85. PubMed ID: 24352219
    [Abstract] [Full Text] [Related]

  • 8. Detection of relapse by sequential monitoring of chimerism in circulating CD34+ cells.
    Thiede Ch, Lutterbeck K, Oelschlägel U, Kiehl M, Steudel Ch, Platzbecker U, Brendel C, Fauser AA, Neubauer A, Ehninger G, Bornhäuser M.
    Ann Hematol; 2002 Feb; 81 Suppl 2():S27-8. PubMed ID: 12611065
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT.
    Rosenow F, Berkemeier A, Krug U, Müller-Tidow C, Gerss J, Silling G, Groth C, Wieacker P, Bogdanova N, Mesters R, Büchner T, Kienast J, Berdel WE, Stelljes M.
    Bone Marrow Transplant; 2013 Aug; 48(8):1070-6. PubMed ID: 23376821
    [Abstract] [Full Text] [Related]

  • 11. Donor Lymphocyte Infusion (DLI) post allogeneic stem cell transplant (allo-SCT) in Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS). A longitudinal retrospective study using peripheral blood (PB) CD34+ and CD3+ donor chimerism (DC) monitoring.
    Indran T, Das T, Muirhead J, O'Brien M, Swain MI, Cirone B, Widjaja J, Patil S, Curtis DJ.
    Leuk Res; 2024 Jul; 142():107504. PubMed ID: 38703634
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ.
    J Clin Oncol; 2005 Aug 20; 23(24):5675-87. PubMed ID: 16110027
    [Abstract] [Full Text] [Related]

  • 16. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR, German Cooperative Transplant Study Group.
    Ann Hematol; 2003 Jun 20; 82(6):336-42. PubMed ID: 12728337
    [Abstract] [Full Text] [Related]

  • 17. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander AR.
    Bone Marrow Transplant; 2001 Oct 20; 28(7):643-7. PubMed ID: 11704786
    [Abstract] [Full Text] [Related]

  • 18. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.
    Pollyea DA, Artz AS, Stock W, Daugherty C, Godley L, Odenike OM, Rich E, Smith SM, Zimmerman T, Zhang Y, Huo D, Larson R, van Besien K.
    Bone Marrow Transplant; 2007 Dec 20; 40(11):1027-32. PubMed ID: 17846595
    [Abstract] [Full Text] [Related]

  • 19. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT.
    Bader P, Beck J, Frey A, Schlegel PG, Hebarth H, Handgretinger R, Einsele H, Niemeyer C, Benda N, Faul C, Kanz L, Niethammer D, Klingebiel T.
    Bone Marrow Transplant; 1998 Mar 20; 21(5):487-95. PubMed ID: 9535041
    [Abstract] [Full Text] [Related]

  • 20. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
    Doubek M, Palasek I, Pospisil Z, Borsky M, Klabusay M, Brychtova Y, Jurcek T, Jeziskova I, Krejci M, Dvorakova D, Mayer J.
    Exp Hematol; 2009 Jun 20; 37(6):659-72. PubMed ID: 19463768
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.